- Recent capital raise removes liquidity risk.
- Last week's board of directors additions strengthen management depth.
- Sales commence in EU as of Q4 2013.
- U.S. trial may be Fast-Tracked.
- Neutrolin may be eligible for GAIN Act status.
Cormedix, Inc. is a development stage pharmaceutical and medical device company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.